Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-31
2010-06-08
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07732476
ABSTRACT:
A method of inducing high anti-leukemia activity responsive to the combination of hydroxamic acid analogue histone deacetylase inhibitors and PKC412 against human acute leukemia characterized as expressing phosphorylated (p)FLT3 kinase by a novel flow cytometry-based assay.
REFERENCES:
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6187543 (2001-02-01), Blackshear
patent: 6552065 (2003-04-01), Remiszewski et al.
patent: 7276612 (2007-10-01), Verner et al.
patent: 2003/0096875 (2003-05-01), Burton et al.
patent: 2004/0152632 (2004-08-01), Feingold
patent: 2004/0180911 (2004-09-01), Capraro et al.
patent: 2005/0020570 (2005-01-01), Griffin et al.
patent: 0 919 244 (1999-06-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 2004/052292 (2004-06-01), None
Weisberg et. al., Cancer Cell, Jun. 2002, 1:433-443.
Gura, Science, 1997, 278:1041-1042.
Johnson, British Journal of Cancer, 2001, 84:1424-1431.
Bali et al., “Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3,” Clinical Cancer Research, 2004, pp. 4991-4997, vol. 10.
Remiszewski et al., N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[[(2-hydroxyethyl)[1H-indo1-3-yl)ethyl]amino]methyl]-phenyl]-2-propenamide (NVP-LAQ824), J. Med. Chem., 2003, pp. 4609-4624, vol. 46.
Lee et al., “Parallel Phase I Studies of Daunorubicin Given With Cytrabine and Etoposide With or Without the Multidrug Resistance Modulator PCS-833 in Previously Untreated Patents 60 years or Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420,” Journal of Clinical Oncology, 1999, pp. 2831-2839, vol. 17, No. 9.
Raffa et al., “Unexpected And Pronounced Antinociceptive Synergy Between Spinal Acetaminophen (Paracetamol) and Phentolamine,” European Journal of Pharmacology, 2001, pp. R1-R2, vol. 412.
Tallarida, “The Interaction Index: A Measure Of Drug Synergism,” Pain, 2002, pp. 163-168, vol. 98.
Tallarida et al., “Antinociceptive Synergy, Additivity, and Subadditivity with Combinations of Oral Glucosamine Plus Nonopioid Analgesics In Mice,” Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 699-704, vol. 307, No. 2.
Tanda et al., “Combinations of Cocaine With Other Dopamine Uptake Inhibitors: Assessment of Additivity,” Journal of Pharmacology and Experimental Therapeutics, Fast Forward, 2009, First published on May 29, 2009; DOI: 10.1124/jpet.109.154302.
Bryan Cave LLP
Krass Frederick
Sznaidman Marcos
University of South Florida
LandOfFree
Leukemia treatment method and composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leukemia treatment method and composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leukemia treatment method and composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161092